Etoricoxib fixed dose

Phase 3Small molecule

LLaboratorios Silanes S.A. de C.V.

Etoricoxib fixed dose is one of 72 small molecule programs targeting Low back pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Back PainActive, not recruiting

ArthritisActive, not recruiting

Low Back PainPhase 3

Active, not recruiting

ArthritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Low Back Pain

#DrugCompanyPhaseTrials

Tofranil

Sanofi

Phase 3

1 2

Pred Forte

Suboxone

4 4

Keterol

PPamukkale University

Phase 3

3 5

Tylenol

KKenvue Brands

Phase 3

3 6

Ultram

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

1 7

Voltaren

CCerimon Pharmaceuticals

Phase 3

1 8

Amoxil

GGlobal Antibiotics Research and Development Partnership

Phase 3

1 9

Xylocaine

MMEDRx USA, Inc.

Phase 3

1 10

Hydrocodone/acetaminophen

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Arthritis

NCT06863701

Clinical

Trials by Indication[1]

Low back pain3 trials

Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm

Completed·LLaboratorios Silanes S.A. de C.V.·Phase 3·NCT06863662·136 enrolled

Efficacy and Safety of Fixed-dose Combination of Etoricoxib/Tramadol vs Acetaminophen/Tramadol for Acute Low Back Pain

Completed·LLaboratorios Silanes S.A. de C.V.·Phase 3·NCT04968158·124 enrolled

Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain

Completed·LLaboratorios Silanes S.A. de C.V.·Phase 3·NCT06517823·190 enrolled

Arthritis1 trial

Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis

Recruiting·LLaboratorios Silanes S.A. de C.V.·Phase 3·NCT06863701·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Etoricoxib fixed dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Etoricoxib fixed dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Etoricoxib fixed dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Laboratorios Silanes S.A. de C.V. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLaboratorios Silanes S.A. de C.V.

Etoricoxib fixed dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Low back pain3 trials

Arthritis1 trial

References

Drug Info

Quick Facts

Related News